Status | Study |
Not yet recruiting |
Study Name: Trial On Trabectedin In The Treatment Of Advanced Uterine And Ovarian Carcinosarcoma (CS)_MITO 26 Condition: Carcinosarcoma, Ovarian Carcinosarcomas Uterine Date: 2016-12-01 Interventions: Drug: Trabectedin Other Name: Yondelis |
Recruiting |
Study Name: Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Condition: Ovarian Brenner Tumor Ovarian Carcinosarcoma Date: 2014-03-28 Interventions: Drug: Gemcitabine Hydrochloride |
Recruiting |
Study Name: Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery or Gynecological Cancers Condition: Cervical Adenosarcoma Cervical Adenosquamous Carcinoma Cer Date: 2013-12-19 Interventions: Biological: Bevacizumab Given |
Terminated |
Study Name: Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Condition: Cancer Date: 2010-05-26 Interventions: Drug: cyproheptadine hydrochloride |
Active, not recruiting |
Study Name: Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy Condition: Cognitive Side Effects of Cancer Therapy Malignant Ovarian Epithelial Tumor Date: 2010-03-03 Interventions: Procedure: Cognitive Assessment |
Active, not recruiting |
Study Name: Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Condition: Adult Hepatocellular Carcinoma Advanced Adult Hepatocellular Carcinoma Date: 2009-11-06 Interventions: Biological: Bevacizumab Given |
Active, not recruiting |
Study Name: Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Condition: Fallopian Tube Carcinosarcoma Fallopian Tube Clear Cell Adenocarcinoma Date: 2009-10-02 Interventions: Biological: Bevacizumab Given |
Not yet recruiting |
Study Name: Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer Condition: Ovarian Carcinosarcoma Recurrent Fallopian Tube Carcinoma Date: 2009-08-06 Interventions: Drug: Paclitaxel Given IV |
Completed |
Study Name: Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial Condition: Cancer Date: 2009-05-16 Interventions: Genetic: gene expression analysis Genetic: |
Active, not recruiting |
Study Name: Two Different Schedules of Carboplatin, Paclitaxel, Gemcitabine, and Surgery in Treating Patients With Newly Diagnosed Stage IIIC or Stage IV Primary Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Condition: Fallopian Tube Cancer Ovarian Cancer Primary Peritoneal Ca Date: 2009-02-05 Interventions: Drug: carboplatin Given IV in |